(Q46962257)

26 December 2017

title

Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis (English)

1 reference

26 December 2017

0 references

Ting-Ting Hong

1

1 reference

26 December 2017

Jinbao Huang

series ordinal

2

1 reference

26 December 2017

Terrance D Barrett

series ordinal

3

1 reference

26 December 2017

Benedict R Lucchesi

series ordinal

4

1 reference

26 December 2017

publication date

5 October 2007

1 reference

26 December 2017

American Journal of Physiology Heart and Circulatory Physiology

published in

1 reference

26 December 2017

volume

294

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

page(s)

H145-55

1 reference

26 December 2017

RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Modulation of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: selective up-regulation of prostacyclin synthesis by COX-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

COX-2 and the cyclopentenone prostaglandins - a new chapter in the book of inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Potential adverse effects of cyclooxygenase-2 inhibition: evidence from animal models of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

The development of COX2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

New insights into the role of COX 2 in inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Effect of COX-1/COX-2 inhibition versus selective COX-2 inhibition on coronary vasodilator responses to arachidonic acid and acetylcholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Risk of cardiovascular events associated with selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Endothelial cell function and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Evidence that a prostanoid produced by cyclo-oxygenase-2 enhances contractile responses of the porcine isolated coronary artery following exposure to lipopolysaccharide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

COX-2 in inflammation and resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Resolution of inflammation: state of the art, definitions and terms

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Pharmacological analysis of cyclooxygenase-1 in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Localization of cyclooxygenase isozymes in cardiovascular tissues of dogs treated with naproxen

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Thrombin generation by exposure of blood to endotoxin: a simple model to study disseminated intravascular coagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

A pharmacokinetic/pharmacodynamic approach vs. a dose titration for the determination of a dosage regimen: the case of nimesulide, a Cox-2 selective nonsteroidal anti-inflammatory drug in the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Lipopolysaccharide-stimulated responses in rat aortic endothelial cells by a systems biology approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

Resolution of inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.00646.2007

10.1152/AJPHEART.00646.2007

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

1 reference

26 December 2017